TY - JOUR
T1 - Upneeq for the treatment of speculum-induced blepharoptosis
AU - Safi, Mustafa
AU - Bacharach, Jason
N1 - Publisher Copyright:
Copyright © 2021 Published by Wolters Kluwer on behalf of ASCRS and ESCRS Published by Wolters Kluwer Health, Inc.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - There are many different etiologies of blepharoptosis. Speculum-induced blepharoptosis can occur after intraocular surgery. A series of patients whose speculum-induced blepharoptosis was successfully treated with the recently U.S. Food and Drug Administration–approved drug Upneeq (oxymetazoline hydrochloride 0.1% ophthalmic solution, RVL Pharmaceuticals, Inc.) is presented.
AB - There are many different etiologies of blepharoptosis. Speculum-induced blepharoptosis can occur after intraocular surgery. A series of patients whose speculum-induced blepharoptosis was successfully treated with the recently U.S. Food and Drug Administration–approved drug Upneeq (oxymetazoline hydrochloride 0.1% ophthalmic solution, RVL Pharmaceuticals, Inc.) is presented.
UR - http://www.scopus.com/inward/record.url?scp=85141324596&partnerID=8YFLogxK
U2 - 10.1097/j.jcro.0000000000000048
DO - 10.1097/j.jcro.0000000000000048
M3 - Article
AN - SCOPUS:85141324596
SN - 2214-1677
VL - 9
SP - E00048
JO - JCRS Online Case Reports
JF - JCRS Online Case Reports
IS - 2
ER -